Akums Group, India’s leading contract development and manufacturing organisation (CDMO), has partnered with a global pharmaceutical giant in a deal worth €200 million (₹1,760 crore) to produce and supply a variety of pharmaceutical formulations for the European market.
As part of the agreement, Akums will receive an upfront payment of €100 million (₹880 crore) to facilitate product development and obtain European regulatory approvals for its oral liquid manufacturing facility.
The collaboration focuses on producing multiple SKUs of oral liquid formulations at Akums’ manufacturing facilities in India, which will be marketed by its global partner across Europe.
This partnership aligns with Akums’ strategy to expand its footprint in Europe and other regulated markets while supporting the Indian government’s ‘Make in India’ initiative by enhancing domestic production for global distribution.
Strengthening global manufacturing presence
Akums currently operates two European-approved facilities for injectables and oral solid dosage forms. The company plans to leverage this new approval to expand its product offerings, adding oral liquid formulations to its portfolio, which already includes tablets, hard gelatin capsules, sachets, ampoules, vials, eye drops, and dry powder injections.
The European regulatory approval process for Akums’ oral liquid facility is expected to be completed by the end of 2026, with commercial production slated to begin in 2027 and continue until 2032.
“This collaboration showcases our manufacturing excellence and world-class R&D capabilities,” stated Sandeep Jain, Managing Director of Akums Group. “By manufacturing these products in India, we optimise costs for global pharma companies and strengthen their supply chains. This partnership is a stepping stone to more collaborations and underscores our commitment to regulated markets.”
Sanjeev Jain, Co-Managing Director of Akums, added, “Collaborating with one of the world’s largest pharmaceutical companies is a significant milestone. It enables us to replicate our domestic CDMO success on a global scale and solidify our presence in Europe’s regulated markets.”
This partnership highlights Akums’ role as a key player in advancing India’s pharmaceutical manufacturing capabilities for international markets.
